https://www.selleckchem.com/pr....oducts/mitoquinone-m
Median age was 67 years, 36% were 70 years, 9% had PS 2, 91% stage IV and 47% were women. In the observation arm, 73% received pemetrexed at progression. Patients in the maintenance arm had a numerically longer OS (median 12.0 vs. 10.0 months; p = .1 and a statistically significant longer PFS (median 3.1 vs. 1.9 months; p less then .01). In multivariable analyses adjusting for baseline characteristics, there was a trend toward improved OS (HR 0.65, 95% CI 0.42-1.01); p = .05), and a significantly improved PFS (HR 0.53
Beğen
Yorum Yap
Paylaş
